Yes, TMS is FDA-cleared for teenagers. In 2022, the FDA cleared the NeuroStar TMS system for use in adolescents ages 15 to 21 with major depressive disorder (MDD), making it the first TMS device specifically authorized for this younger population. This landmark decision marked a significant turning point for families searching for effective, non-medication alternatives for teen depression.
Transcranial magnetic stimulation (TMS) is a non-invasive brain stimulation treatment used for various mental health conditions. Unlike medications that circulate through the entire body, TMS targets specific regions of the brain using focused magnetic pulses. Patients can return to their daily activities immediately after the procedure.
During a TMS session, a magnetic coil is placed against the scalp near the forehead. The coil delivers brief magnetic pulses to the prefrontal cortex – the brain region responsible for mood regulation and executive functioning. These pulses, similar in strength to those used in an MRI, stimulate underactive nerve cells and gradually restore healthier patterns of brain activity over the course of multiple sessions.
Each session typically lasts between 3 and 40 minutes, depending on the specific types of TMS being used. A full treatment course generally spans several weeks of regular sessions. The procedure is performed while the patient is awake and alert.
TMS has demonstrated effectiveness across a growing list of mental health and neurological conditions. The FDA has cleared TMS devices for:
Major depressive disorder (MDD)
Obsessive-compulsive disorder (OCD)
Anxious depression
Smoking cessation
Beyond these cleared indications, clinicians also use TMS to address conditions such as ADHD, PTSD, and insomnia. You can explore a full list of conditions treated by TMS to understand the therapy’s broader applications.
The FDA first cleared TMS for the treatment of major depressive disorder in adults in 2008. This was a pivotal moment that provided a much-needed alternative for individuals struggling with depression that did not improve with medication. Since then, multiple TMS devices have received clearance for additional conditions, including traditional repetitive TMS (rTMS) and deep TMS devices, each designed to reach different brain structures with varying depths and frequencies.
This history of careful, evidence-based clearance in adults laid the groundwork for exploring the potential benefits of TMS in younger populations.
The 2022 FDA clearance of NeuroStar for adolescents ages 15 to 21 was a landmark event. Prior to this decision, TMS was only formally authorized for adults aged 22 and older with MDD. Clinicians who treated younger patients did so on an off-label basis, relying on emerging research and clinical judgment.
FDA clearance gave providers an evidence-backed pathway to treat adolescent depression with TMS. For parents navigating their teen’s mental health challenges, this clearance provided important reassurance about both the safety and effectiveness of the treatment.
It is important to note that clearance applies specifically to MDD. Other conditions that TMS can treat in adults have not yet received separate FDA clearance for the adolescent population.
The FDA clearance specifies a minimum age of 15 years old. Patients younger than 15 are not included in the current authorization. For teens who meet the age requirement, the primary indication is major depressive disorder, particularly cases where standard treatments have not produced adequate results. To qualify, a teenager typically needs to have:
A formal diagnosis of major depressive disorder
An inadequate response to at least one prior antidepressant medication trial
No contraindications for TMS (such as metallic implants near the treatment area or a history of seizures)
A qualified mental health provider will conduct a thorough evaluation before recommending TMS for any adolescent patient.
Teen depression is a growing concern. Millions of adolescents in the United States experience at least one major depressive episode a year. Many of these young people do not respond fully to first-line treatments like therapy and medication, leaving families searching for additional options.
Clinical data indicate that a significant percentage of adolescents who undergo TMS experience meaningful reductions in depressive symptoms. Many achieve full remission – a complete resolution of depressive symptoms – after completing a treatment course. This level of efficacy is particularly encouraging, offering a path to wellness for teens who may have felt hopeless after trying other treatments.
The non-invasive nature of TMS is especially appealing for this age group. Unlike antidepressants, which can carry side effects such as weight gain, fatigue, and emotional blunting, TMS does not introduce any chemicals into the body. The therapy can help restore mental wellness and dramatically improve outcomes.
The FDA’s decision was based on a prospective, randomized, controlled clinical trial specifically designed to evaluate the safety and effectiveness of TMS in adolescents with MDD. The results showed statistically significant improvement in standardized depression rating scores for the group receiving active TMS compared to the sham (placebo) treatment group. Additional studies published in peer-reviewed journals have reinforced these findings, showing that:
Adolescents tolerate TMS well, with dropout rates comparable to or lower than adult populations
Response rates in teens are encouraging, with many showing improvement within the first few weeks
The benefits of TMS can extend beyond the treatment period, with many adolescents maintaining improvement at follow-up assessments
For families who have watched their teenager struggle despite medication changes and therapy sessions, these results offer genuine hope. Learning how to overcome depression can start with understanding all available treatment pathways.
One of the most reassuring aspects of TMS is its safety profile. Because TMS is not systemic, it does not cause the widespread side effects associated with antidepressants, such as weight gain, sexual dysfunction, drowsiness, or gastrointestinal issues. The most commonly reported side effects in teenagers include:
Scalp discomfort at the site where the magnetic coil is placed
Mild headache during or after sessions, which typically resolves on its own or with over-the-counter pain relief
Lightheadedness that passes shortly after treatment
Tingling sensation on the scalp during pulse delivery
These side effects tend to decrease as treatment progresses and the patient becomes accustomed to the sensation. Most teens are able to return to school, sports, and other activities immediately after each session.
Not every mental health provider offers TMS, and not every TMS clinic treats adolescents. Finding a qualified provider with experience in adolescent TMS is an important step. Parents should look for clinics that:
Use FDA-cleared devices authorized for the 15-to-21 age group
Have trained technicians and supervising clinicians experienced with younger patients
Conduct thorough pre-treatment evaluations, including psychiatric assessment and medical history review
Offer personalized treatment protocols tailored to the adolescent’s specific needs
Our directory can be a valuable resource for TMS providers in your area. You can also search for a clinic by visiting the Find a TMS Clinic page and entering your location.
The FDA clearance of TMS for adolescents ages 15 to 21 represents a transformative advancement in how we approach teen depression. TMS offers a non-invasive, medication-free treatment pathway that is well-tolerated by younger patients. As research expands to investigate TMS for additional adolescent conditions such as ADHD, the potential applications for this therapy will likely broaden further. For now, teens with treatment-resistant major depressive disorder have a powerful, FDA-cleared option that can make a real difference in their mental health and daily functioning.
In recent years, TMS has emerged as a promising option for teenagers struggling with depression that has not improved with traditional treatments. With FDA clearance for adolescents ages 15 to 21, parents now have access to a safe, non-invasive therapy backed by growing clinical evidence. While TMS may not be the right fit for every teen, it offers new hope for families seeking effective alternatives beyond medication alone.
By working with qualified providers and understanding the treatment process, parents can make informed decisions about whether TMS could play a meaningful role in their teenager’s mental health journey.
About the Author
TMS Therapy Near Me
May 29, 2026
